CyDex Pharmaceuticals names new president and CEO
Mr Odlaug replaces John Siebert, who has retired as CyDex’s CEO and has stepped down as chairman of the company’s board of directors. Siebert will remain a consultant
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).